Try our Advanced Search for more refined results

Mylan Loses Bid To Overturn Insomnia Drug Patent

By Sophia Dourou ( May 27, 2022, 5:21 PM BST) -- Generic drugmaker Mylan has lost its fight to invalidate two Neurim patents for an insomnia treatment, as a London appeals court found on Friday that there was nothing wrong with the way sleep quality was assessed in studies evaluating the drug....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms